Verastem’s (VSTM) Buy Rating Reaffirmed at HC Wainwright

Posted by George Bondi on Oct 6th, 2026

HC Wainwright reaffirmed their buy rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a research note issued to investors on Monday, Marketbeat reports. HC Wainwright currently has a $18.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on VSTM. BTIG Research restated a “buy” rating and issued a $18.00 price objective on shares of Verastem in a research note on Friday, September 11th. Jefferies Financial Group dropped their target price on Verastem from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, June 23rd. Guggenheim set a $12.00 price target on shares of Verastem and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings raised shares of Verastem from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Verastem in a research note on Monday, September 28th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.83.

View Our Latest Research Report on VSTM

Verastem Price Performance

Shares of VSTM opened at $8.00 on Monday. The company has a debt-to-equity ratio of 1.48, a current ratio of 2.25 and a quick ratio of 2.22. The company’s fifty day moving average price is $7.25 and its 200-day moving average price is $5.78. Verastem has a 1-year low of $3.43 and a 1-year high of $10.82. The firm has a market capitalization of $724.48 million, a PE ratio of -3.01 and a beta of 0.39.

Verastem (NASDAQ:VSTM – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.08. Verastem had a negative return on equity of 467.49% and a negative net margin of 231.59%.The company had revenue of $40.08 million during the quarter, compared to analyst estimates of $22.88 million. On average, equities research analysts predict that Verastem will post -1.56 EPS for the current year.

Insider Buying and Selling at Verastem

In related news, CEO Dan Paterson sold 44,121 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $8.00, for a total transaction of $352,968.00. Following the sale, the chief executive officer directly owned 652,712 shares of the company’s stock, valued at approximately $5,221,696. This represents a 6.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 48,044 shares of company stock worth $381,484. 1.94% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Royal Bank of Canada raised its position in shares of Verastem by 15.3% in the first quarter. Royal Bank of Canada now owns 110,729 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 14,683 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Verastem during the 4th quarter worth approximately $117,000. Bank of New York Mellon Corp grew its position in shares of Verastem by 31.8% in the first quarter. Bank of New York Mellon Corp now owns 161,707 shares of the biopharmaceutical company’s stock valued at $857,000 after purchasing an additional 39,018 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Verastem in the first quarter valued at approximately $210,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Verastem in the first quarter valued at approximately $377,000. Institutional investors and hedge funds own 88.37% of the company’s stock.

Verastem Company Profile

(Get Free Report)

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.